Literature DB >> 81320

Papain solubilization of the Epstein-Barr virus-induced membrane antigen.

G R Pearson, L F Qualtiere.   

Abstract

The Epstein-Barr virus (EBV)-induced membrane antigen (MA) was successfully solubilized from the membranes of viable EBV-infected Raji cells by treatment with papain (5 to 6 U per 1 X 10(7) to 2 X 10(7) cells). The loss of MA from viable cells was monitored by membrane immunofluorescence and antibody-dependent cellular cytotoxicity. Soluble MA was demonstrated in papain digests through inhibition of antibody-dependent cellular cytotoxicity and by inhibition of the binding of anti-MA antibodies to cells as detected by use of 125I-labeled staphylococcal protein A. Approximately 75% of the MA activity in the extracts was not sedimentable at 100,000 X g,, indicating that the majority of EBV MA activity that was released by this procedure was associated with small-molecular-weight material. Antiserum prepared from an owl monkey immunized with these papain extracts contained antibody to MA and neutralizing antibodies, but lacked detectable antibodies against viral capsid antigens and EBV-induced early antigens.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 81320      PMCID: PMC354273          DOI: 10.1128/JVI.28.1.344-351.1978

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  21 in total

1.  Antibody patterns in different human sera against intracellular and membrane-antigen complexes associated with Epstein-Barr virus.

Authors:  A Svedmyr; A Demissie; G Klein; P Clifford
Journal:  J Natl Cancer Inst       Date:  1970-03       Impact factor: 13.506

2.  Comparison between two antibody populations in the EBV system: anti-MA versus neutralizing antibody activity.

Authors:  A de Schryver; A Rosén; P Gunvén; G Klein
Journal:  Int J Cancer       Date:  1976-01-15       Impact factor: 7.396

3.  Epstein-Barr virus--is it time to develop a vaccine program?

Authors:  M A Epstein
Journal:  J Natl Cancer Inst       Date:  1976-04       Impact factor: 13.506

4.  Antibody-dependent lymphocyte cytotoxicity against cells expressing Epstein-Barr virus antigens.

Authors:  G R Pearson; T W Orr
Journal:  J Natl Cancer Inst       Date:  1976-03       Impact factor: 13.506

5.  Cytotoxic effector cells specific for B Cell lines transformed by Epstein-Barr virus are present in patients with infectious mononucleosis.

Authors:  E Svedmyr; M Jondal
Journal:  Proc Natl Acad Sci U S A       Date:  1975-04       Impact factor: 11.205

6.  A solid-phase radioimmunoassay for Epstein-Barr virus-associated membrane antigen prepared from B95-8 cell culture supernatants.

Authors:  G Dölken; G Klein
Journal:  J Natl Cancer Inst       Date:  1977-05       Impact factor: 13.506

7.  Solubilization and characterization of Herpesvirus saimiri-induced membrane antigens.

Authors:  L F Qaultiere; G R Pearson
Journal:  J Virol       Date:  1978-03       Impact factor: 5.103

8.  Membrane immunofluorescence reactions of Burkitt lymphoma cells from biopsy specimens and tissue cultures.

Authors:  G Klein; P Clifford; E Klein; R T Smith; J Minowada; F M Kourilsky; J H Burchenal
Journal:  J Natl Cancer Inst       Date:  1967-11       Impact factor: 13.506

9.  Differentiation between early and late membrane antigen on human lymphoblastoid cell lines infected with Epstein-Barr virus. II. Immunoelectron microscopy.

Authors:  D Silvestre; I Ernberg; C Neauport-Sautes; F M Kourilsky; G Klein
Journal:  J Natl Cancer Inst       Date:  1974-07       Impact factor: 13.506

10.  Relationship between the EBV-associated membrane antigen on Burkitt lymphoma cells and the viral envelope, demonstrated by immunoferritin labelling.

Authors:  D Silvestre; F M Kourilsky; G Klein; Y Yata; C Neauport-Sautes; J P Levy
Journal:  Int J Cancer       Date:  1971-09-15       Impact factor: 7.396

View more
  6 in total

1.  Epstein-Barr virus (EBV) glycoprotein gp350 expressed on transfected cells resistant to natural killer cell activity serves as a target antigen for EBV-specific antibody-dependent cellular cytotoxicity.

Authors:  M Khyatti; P C Patel; I Stefanescu; J Menezes
Journal:  J Virol       Date:  1991-02       Impact factor: 5.103

2.  In vitro cytotoxicity against Marek's disease lymphoblastoid cell lines after enzymatic removal of Marek's disease tumor-associated surface antigen.

Authors:  K A Schat; K K Murthy
Journal:  J Virol       Date:  1980-04       Impact factor: 5.103

3.  Correlation between Epstein-Barr virus membrane antigen and three large cell surface glycoproteins.

Authors:  B C Strnad; R H Neubauer; H Rabin; R A Mazur
Journal:  J Virol       Date:  1979-12       Impact factor: 5.103

4.  Polypeptides of the Epstein-Barr virus membrane antigen complex.

Authors:  D A Thorley-Lawson; C M Edson
Journal:  J Virol       Date:  1979-11       Impact factor: 5.103

5.  Four Decades of Prophylactic EBV Vaccine Research: A Systematic Review and Historical Perspective.

Authors:  Gabriela M Escalante; Lorraine Z Mutsvunguma; Murali Muniraju; Esther Rodriguez; Javier Gordon Ogembo
Journal:  Front Immunol       Date:  2022-04-14       Impact factor: 8.786

6.  Early events associated with infection of Epstein-Barr virus infection of primary B-cells.

Authors:  Sabyasachi Halder; Masanao Murakami; Subhash C Verma; Pankaj Kumar; Fuming Yi; Erle S Robertson
Journal:  PLoS One       Date:  2009-09-28       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.